Authors and Disclosures
|
|
- Samson Nichols
- 6 years ago
- Views:
Transcription
1 Role of Carbon Dioxide-Releasing Suppositories in the Treatment of Chronic Functional Constipation A Double-Blind, Randomised, Placebo-Controlled Trial M. Lazzaroni; V. Casini; G. Bianchi Porro Authors and Disclosures M. Lazzaroni, V. Casini and G. Bianchi Porro, Gastrointestinal Unit, L. Sacco University Hospital, Milan, Italy Disclosure: The authors have no potential conflicts of interest that are directly relevant to the contents of this article. Posted: 08/10/2005; Clin Drug Invest. 2005;25(8): Adis Data Information BV Physician Rating: Abstract and Introduction 1 / 9
2 Abstract Objective: Treatment of chronic functional constipation is difficult. Both oral and topical laxatives may fail to adequately relieve symptoms, and there is risk of adverse effects such as functional or structural changes in the intestine, together with electrolyte disturbances. The aim of this study was to evaluate the efficacy and safety of a suppository that combines sodium bicarbonate and potassium bitartrate in a polyethylene glycol base to generate approximately 175mL of carbon dioxide (CO 2 ). This release distends the rectal ampulla, thereby stimulating peristalsis and a subsequent bowel movement. Patients and Methods: This was a prospective, crossover, double-blind, randomised, placebo-controlled, sequential study of outpatients with chronic functional constipation. Each patient received two suppositories of identical appearance, containing active drug or placebo. The sequence of active drug-placebo (sequence 1) or placebo-active drug (sequence 2) was randomised in groups of eight. The second suppository was taken 7 days after the first. The following parameters were evaluated and scored: evacuation time, type of evacuation, feeling of emptying of the rectal ampulla, stool characteristics, anal complaints, abdominal pain and overall patient assessment. Results: A total of 29 patients entered the study. According to a restricted sequential plan, a statistical significance (p < 0.05) in favour of the active drug was reached after 26 patients. A positive response within 30 minutes of introduction of the suppository occurred in 51.7% and 6.9% of patients treated with the active drug and placebo, respectively (p = ). Normal evacuation occurred in 65.5% and 24.1% of patients treated with the active drug and placebo, respectively (p = 0.004). Normal stool consistency was found in 44.8% and 7.2% of patients treated with the active drug and placebo, respectively (p = 0.04). Patient assessment of treatment as satisfactory occurred in 51.7% and 20.7% of subjects treated with the active drug and placebo, respectively (p = 0.029). Only a trend in favour of the active drug was observed with regard to feeling of incomplete evacuation, and active drug was comparable to placebo with regard to anal and abdominal tolerability Conclusion: The CO 2 -releasing suppository may represent an alternative to rectal laxatives for the relief of chronic functional constipation. The data obtained in this study indicate that CO 2-releasing suppositories may be usefully and safely employed in the treatment of patients at risk for electrolyte disorders such as the elderly or patients with renal or cardiovascular disorders. Introduction Treatment of chronic functional constipation is a difficult challenge. In more severe forms of the condition, both bulking agents and oral laxatives may fail to adequately relieve symptoms, while introducing the risk of adverse effects such as abdominal pain, functional or structural changes in the intestine (increased apoptosis of colonic epithelial cells), electrolyte disturbances and abdominal distension. [1] 2 / 9
3 The combination of oral and rectal laxatives such as stimulating suppositories, hyperosmolar enemas and faecal softening agents may contribute to satisfactory emptying of the rectum by reducing straining at stool. The results are, however, unpredictable [2] and there is evidence that stimulating suppositories and hyperosmolar enemas are not as completely harmless as they have been believed to be. [3] The present investigation was carried out to evaluate the efficacy and safety of a suppository that combines sodium bicarbonate and potassium bitartrate, in a polyethylene glycol base, to generate approximately 175mL of carbon dioxide (CO 2 ). [4,5] This release distends the rectal ampulla, thereby stimulating peristalsis and a subsequent bowel movement, usually within 30 minutes of introduction.suppositories, hyperosmolar enemas and faecal softening agents may contribute to satisfactory emptying of the rectum by reducing straining at stool. The results are, however, unpredictable [2] and there is evidence that stimulating suppositories and hyperosmolar enemas are not as completely harmless as they have been believed to be. [3] The present investigation was carried out to evaluate the efficacy and safety of a suppository that combines sodium bicarbonate and potassium bitartrate, in a polyethylene glycol base, to generate approximately 175mL of carbon dioxide (CO 2 ). [4,5] This release distends the rectal ampulla, thereby stimulating peristalsis and a subsequent bowel movement, usually within 30 minutes of introduction. Patients and Methods Patients Outpatients >18 years of age with chronic functional constipation defined according to R ome II criteria [6] were enrolled in the study. All patients had normal haematological and biochemical test results, and were ineligible for the study if organic disease of the upper and lower gastrointestinal tract in the last year had not been ruled out by endoscopy or x-rays. 3 / 9
4 Other exclusion criteria were: drug-induced constipation; central or peripheral neurological abnormalities; metabolic and endocrine disorders (diabetes mellitus, porphyria, hypothyroidism, hyper- parathyroidism and hypercalcaemia); acute or chronic hepatic and/or renal disorders; and previous anorectal surgery. It was a prerequisite that female patients enrolled in the study were not pregnant or breast-feeding, and were postmenopausal, surgically sterilised or using adequate contraception. Evaluation Criteria The following parameters were evaluated: a. Evacuation time, evaluated on a three-point scale as follows: 1 = <15 minutes, 2 = >15 minutes but <30 minutes, 3 = >30 minutes; b. Characteristics of evacuation, evaluated on a two-point scale as follows: 1 = normal, 2 = difficult; c. Feeling of emptying of the rectum, evaluated on a two-point scale as follows: 1 = complete, 2 = incomplete; d. Characteristics of the stools, evaluated on a three-point scale as follows: 1 = normal, 2 = soft; 3 = hard; e. Anal complaints, evaluated on a four-point scale as follows: 1 = absent, 2 = anal itch, 3 = anal irritation, 4 = anal pain; f. Abdominal pain, evaluated on a four-point scale as follows: 1 = absent, 2 = mild, 3 = moderate, 4 = severe; and g. Patient's overall assessment, evaluated on a two-point scale as follows: 1 = satisfied, 2 = not satisfied. Using this evaluation system, an overall score ranging from a minimum of 8 (positive effect) to a maximum of 20 (no effect) was obtained. The active drug was considered superior to the placebo if a score at least 3 points lower than that of the placebo was reached. If the score was 2 points or less lower, the active drug and the placebo were considered equivalent. Treatment In this crossover, prospective, double-blind, randomised, placebo-controlled, sequential study, each patient received two suppositories of identical appearance, containing either active drug (CEO-two, Beutlich, Inc., Niles, IL, USA) 1 or placebo. The sequence of active drug-placebo (sequence 1) or placebo-active drug (sequence 2) was randomised in groups of eight. The second suppository was taken 7 days after the first. Evaluation scores and all adverse events were recorded in a daily diary. Use of oral laxatives and rectal administration of enemas or suppositories was not permitted in the 2 days prior to administration of the study medication. Patients were also encouraged to take about 30g of non-starch polysaccharide daily. Within 48 hours of the end of treatment, patients were again interviewed and compliance with treatment, clinical status and diary cards were evaluated. Ethics 4 / 9
5 The study was approved by the local Ethics Committee of the L. Sacco University Hospital, Milan, Italy. All study participants provided written informed consent prior to the start of the study. Statistical Evaluation A restricted sequential plan with upper, lower and middle boundaries (according to Armitage [7] ) was applied with the following specifications: type I error alpha: 0.05; power (1 minus beta): 0.95; proportion of preferences in favour of the active drug (theta value) 0.80; null hypothesis 50; maximum size of trial 40 pairs of treatments. The trial was completed as soon as the trial results plot reached one of the boundaries. If the upper boundary was reached first, the active drug was significantly superior to placebo; if the lower boundary was reached first, placebo was significantly superior to active drug; if the middle boundary was reached this was considered as no evidence of a treatment difference. Statistical analysis was also carried out using Student's t-test, the chi-square (? 2 ) test (with Yates' correction) and Fisher's exact test when needed. Scores were analysed by means of Koch's non-parametric test for crossover trials. A p-value <5% was considered significant. Results Patients A total of 29 patients entered the study. The two groups were similar in mean age, sex distribution and previous treatment with laxatives other than bulk agents ( table I ). Efficacy The upper boundary was reached when patient #26 expressed the fifteenth valid preference for the active drug, thus showing that the active suppository was significantly superior to the placebo (p < 0.05) [figure 1]. 5 / 9
6 Figure 1. Sequential plan of the study according to Armitage.[7] The upper boundary was reached when patient #2 Figure 1. Sequential plan of the study according to Armitage.[7] The upper boundary was reached when patient #26 expressed the fifteenth valid preference for the active drug, thereby showing significant superiority of the active suppository over placebo (p < 0.05). Evacuation Time. A positive response occurred within 30 minutes of introduction of the suppository (score 1 plus 2) in 51.7% (15 of 29) of the patients treated with the active drug; the percentage after placebo was 6.9% (2 of 29). This difference was significant (p = ) [ table II ]. A score of 1 (positive response within 15 minutes) was recorded in 7 of 29 (24.1%) patients treated with active drug but in no patients treated with placebo. The median scores on the evacuation time scale after active drug and placebo were 2.43 and 2.96, respectively (p < 0.001). Evacuation Characteristics. Normal evacuation was reported by 19 of 28 (65.5%) and 7 of 29 (24.1%) patients treated with the active drug and placebo, respectively (p = 0.004) [ ta ble II ]. Analysis of scores according to Koch's criteria showed a statistically significant difference in favour of the active drug. Feeling of Emptying of the Rectum. A feeling of incomplete evacuation was reported by 16 of 29 patients (55.2%) after the active drug and 23 of 29 (79.3%) after placebo (p = 0.093) [ table II ]. Stool Characteristics. Normal consistency of the stools was reported in 13 of 29 (44.8%) and in 5 of 29 (7.2%) of patients treated with the active drug and placebo, respectively (p = 0.04) [ table II ]. However, no difference was observed in the analysis of median scores because of a statistically significant carryover effect. Patients' Overall Assessment. Treatment was assessed as satisfactory by 15 of 29 6 / 9
7 (51.7%) and 6 of 29 (20.7%) patients treated with the active drug and placebo, respectively (p = 0.029) [ table II ]. A significant difference in favour of the active drug was also observed in relation to median scores. Safety Anorectal Complaints. No symptoms were reported by 25 of 29 (86.2%) patients after the active drug and 26 of 29 patients (89.7%) after placebo; local irritation occurred in 4 of 29 patients after active drug and in 3 of 29 patients after placebo ( table II ). The median scores according to sequence of administration were similar. Abdominal Pain. No symptoms were reported by 18 of 29 (62.1%) patients after the active drug and 23 of 29 patients (79.3%) after placebo (p = 0.249); moderate pain was reported by 2 of 29 (6.8%) patients after the active drug. In no case was severe abdominal pain reported ( table II ). The median scores according to sequence of administration were similar. Discussion Most experts recommend that patients with chronic functional constipation first increase their intake of dietary fibre. [8] Fibre intake may be increased by changing the composition of the diet or by adding medicinal fibre or bulk-forming agents. Although increasing dietary fibre can increase stool frequency and bulk, it may lead to increased bloating and may be unhelpful in patients with severe colonic inertia or dyschezia. [9,10] Moreover, it has been observed that patients complaining of constipation do not eat less dietary fibre than matched healthy control subjects. [11,12] In most chronically constipated patients, oral laxatives are administered alone or, particularly in patients with outlet obstruction constipation, combined with rectal stimulating suppositories, hyper- osmolar enemas or faecal softening agents. In most cases rectal laxatives are widely used for long periods without any medical controls. However, the effect on the rectal mucosa of long-term administration of such agents has not been studied. [13] There are occasional severe adverse reactions due to inadvertent introduction and retention of large volumes of water enema or hypertonic solutions. [14] Metabolic effects are potentially dangerous in small children or in adults with cardiovascular or renal impairment. [1] 7 / 9
8 Rectal laxatives may stimulate contraction by distension or chemical action (stimulation). Action, mainly by distension, is observed after a saline or water enema. Water does not induce adverse effects on the mucosa, but if large volumes (1-2L) are retained, dangerous water intoxication may occur. [13] Sodium phosphate enemas act by distension and stimulation. They are usually successful in the treatment of occasional rectal evacuation, but their long-term use may induce mild to severe lesions in the rectal mucosa. [15] Furthermore, if there is any disorder that prevents prompt evacuation, use of phosphate enemas can lead to dangerous hyper- phosphataemia and hypocalcaemic tetanus in children or patients with renal impairment. [16,17] Glycerine and bysacodil exert a stimulating effect, but the latter may produce marked changes in epithelial cells to varying depths within the crypts. [15] The availability of a suppository that stimulates bowel movements without the risk of passage of large liquid stools, water retention or mucosal damage may represent an interesting alternative to the current rectal laxatives, particularly in patients at risk because of age or organic disease. The active drug combines sodium bicarbonate and potassium bitartrate, in a polyethylene glycol base, to generate approximately 175mL of CO 2. [4,5] CO 2 is an important component of intestinal gas, which, in physiological conditions, is produced by fermentative degradation of carbohydrates and cellulose. In adequate amounts, CO 2 stimulates peristalsis, increases microcirculation permeability without histopathological damage, and promotes defaecation. The choice of the duration of washout period from laxatives in this study was arbitrary. However, we believe that a 2-day washout from laxatives other than bulk-forming laxatives was sufficient to minimise the influence of laxatives on the study drug. Furthermore, the number of patients taking laxatives in the two arms of the study was similar. 8 / 9
9 No stratification by age was performed in this study. While this might have provided useful clinical information, the patient series was too small to have allowed valid statistical conclusions to be drawn regarding any possible effects of patient age on treatment. The results of our study appear to confirm the clinical usefulness of the product under investigation. When compared with placebo, the active drug significantly decreased evacuation time: a bowel movement occurred within 15 minutes of introduction of the suppository in 24% of patients, and within 30 minutes in 52% of patients. The corresponding figures after placebo were significantly lower (0% and 7%, respectively). The active drug also reduced straining during bowel movements in 66% of patients, and improved stool characteristics in 45% of patients. No difference between the active drug and placebo was noted in the feeling of emptying of the rectal ampulla. This finding is not easy to explain, but may indicate a residual effect of distension of the ampulla by CO 2. It is also worth noting that overall patient assessment of clinical efficacy was significantly in favour of the active drug: 52% of patients expressed a preference for the active drug compared with 21% for placebo. The active drug was well tolerated. The percentage of anal complaints was similar to that for placebo (14% vs 11% of cases). Abdominal pain was reported as mild in 31% of patients and moderate in 7% of patients after the active drug; these figures were not significantly different to those after placebo. Conclusion The active drug is an interesting alternative to rectal laxatives, when administered alone or combined with oral laxatives, for the relief of chronic functional constipation. In our opinion, the compound acts on mechanisms that do not involve risks of mucosal damage or electrolyte imbalance and can be proposed for short-term treatment even in patients at risk for electrolyte disorders, such as, for instance, the elderly or patients with renal or cardiovascular impairment. Long-term use in such patients, however, warrants further study. 9 / 9
Identify electrolytes that should be monitored whenever prolonged or severe diarrhea is present
Chapter 35 Drugs Used to Treat Constipation and Diarrhea Learning Objectives State the underlying causes of constipation Explain the meaning of normal bowel habits Cite nine causes of diarrhea Describe
More informationChapter 31 Bowel Elimination
Chapter 31 Bowel Elimination Defecation Defecation: the act of expelling feces from the body Peristalsis: rhythmic contractions of intestinal smooth muscle to facilitate defecation Gastrocolic reflex:
More informationConstipation Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.uk
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Constipation Constipation is a symptom that can mean different things to different people but the usual
More informationMOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l
MOVICOL -Half Powder for Solution (macrogol 3350) Product Name: Product Description: MOVICOL-Half Each sachet of MOVICOL-Half contains: Macrogol 3350 6.563 g Sodium chloride 175.4 mg Sodium bicarbonate
More informationActive ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate.
NAME OF THE MEDICINE KLYX Enema Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate Sorbitol C20H37NaO7S MW: 444.56 CAS no: 577-11-7
More informationMOVICOL Junior Powder for Solution (macrogol 3350)
MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride
More informationConstipation. What is constipation? What is the criteria for having constipation? What are the different types of constipation?
What is constipation? is defined as having a bowel movement less than 3 times per week. It is usually associated with hard stools or difficulty passing stools. You may have pain while passing stools or
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More informationMOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)
MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Chocolate Flavour Product Description: Each sachet of MOVICOL Junior Chocolate contains: Macrogol 3350
More informationThe Digestive System or tract extends from the mouth to the anus.
The Digestive System or tract extends from the mouth to the anus. FUNCTION The Digestive System breaks down and absorbs food materials e.g. amino acids, glucose DEFINITIONS: Ingestion: Ingestion is the
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationEfficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club
Efficacy and Safety of Lubiprostone Laura Wozniak February 23, 2010 K30 Monthly Journal Club Objectives Brief overview of constipation Review of article Discussion Constipation in Children 3-5% of all
More informationConstipation an Old Friend. Presented by Dr. Keith Harris
Constipation an Old Friend Presented by Dr. Keith Harris Irregularity and the Tricks of the Trade." CONSTIPATION What is constipation? INFREQUENT BOWEL MOVEMENTS DIFFICULTY DURING DEFECATION SENSATION
More informationMOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)
MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.
More informationWhat Is Constipation?
CONSTIPATION What Is Constipation? Constipation is when you have infrequent or hard-to-pass bowel movements (meaning they are painful or you have to strain), have hard stools or feel like your bowel movements
More informationUnderstanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class
Understanding & Alleviating Constipation Living (Well!) with Gastroparesis Program Warm-Up Class Please Remember The information presented is for educational purposes only and is in no way intended as
More informationConstipation and bowel obstruction
Constipation and bowel obstruction Constipation Infrequent or difficult defecation with reduced number of bowel movements, which may or may not be abnormally hard with increased difficulty or discomfort
More informationMOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350)
MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Lemon-Lime Flavour Product Description: Each sachet of MOVICOL Lemon-Lime contains: Macrogol 3350 Sodium chloride Sodium
More informationConstipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment
CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Macrovic Junior powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution
More informationA guide to Anoplasty (anal surgery)
Saint Mary s Hospital Newborn Intensive Care Unit Information for Parents A guide to Anoplasty (anal surgery) Introduction This information leaflet is designed to help parents and families to care for
More informationGastrointestinal Involvement in Adult Mitochondrial Disease
Newcastle Mitochondrial Disease Guidelines At a glance guidelines: Gastrointestinal Involvement in Adult Mitochondrial Disease For full guideline visit: http://www.newcastle-mitochondria.com/service/patient-care-guidelines/
More informationProtectives and Adsorbents. Inorganic chemistry Course 1 Third year Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry
Protectives and Adsorbents Inorganic chemistry Course 1 Third year 2016-2017 Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry Protectives and Adsorbents This group of gastrointestinal agents
More informationPRODUCT INFORMATION RESONIUM A. Na m
PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION
More informationNursing Principles & Skills II. Bowel Sounds Constipation Fecal Impaction
Nursing Principles & Skills II Bowel Sounds Constipation Fecal Impaction Bowel Sounds Definitionthe noise or sounds made by the peristaltic waves of the intestinal muscle contracting and relaxing Bowel
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active
More informationOPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationPackage leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides
Package leaflet: Information for the user SenEase 7.5 mg tablets Sennosides Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep
More informationMOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-
MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan- This material is an English translation of the press release issued on November 29, 2018 in Japanese,
More informationMOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-
November 29, 2018 EA Pharma Co., Ltd. Eisai Co., Ltd. Mochida Pharmaceutical Co., Ltd. MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan- EA Pharma
More informationWHICH BOWEL PREPARATION WORKS BEST? A RANDOMISED CONTROL TRIAL. Nicole Weston Senior Oncology and Palliative Care Dietitian 18 th May 2017
WHICH BOWEL PREPARATION WORKS BEST? A RANDOMISED CONTROL TRIAL Nicole Weston Senior Oncology and Palliative Care Dietitian 18 th May 2017 Background Lack of prospective, adequately powered trials to identify
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Constipation: management of idiopathic constipation in children in primary and secondary care 1.1 Short title Constipation
More informationConstipation. Disease Review
bowel. 1 Constipation is a symptom, not a disease. Almost everyone experiences Disease Review Constipation Introduction: Constipation is exceedingly common and is rarely associated with mortality in developed
More informationPrescribing Guidance for the Treatment of Constipation in Children
Prescribing Guidance for the Treatment of Constipation in Children Effective Date: July 2007 Reviewed: September 2009 & December 2011 Review Date: December 2013 Gateshead Medicines Management Approved
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Constipation: the diagnosis and management of idiopathic childhood constipation in primary and secondary care 1.1 Short title
More information15. Prevention of UTI and lifestyle modifications
15. Prevention of UTI and lifestyle modifications Key questions: Does improving poor voiding habits help prevent UTI recurrence? Does improving constipation help prevent UTI recurrence? Does increasing
More informationConstipation. Information for adults. GI Motility Clinic (UMCCC University Medical Clinics of Campbelltown and Camden) Page 1
Constipation Information for adults GI Motility Clinic (UMCCC University Medical Clinics of Campbelltown and Camden) Page 1 Contents Role of the large intestine..3 Mass movements in the large intestine..4
More informationChapter 19. Assisting With Bowel Elimination. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.
Chapter 19 Assisting With Bowel Elimination Normal Bowel Elimination Time and frequency of bowel movements (BMs) vary. To assist with bowel elimination, you need to know these terms: Defecation is the
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g
More informationManaging constipation in residential care
Managing constipation in residential care Amanda Lee Lecturer, Hull University ; PhD Candidate, Gastroesophageal cancers Key Points Constipation is a major problem in residential care Early detection and
More informationDulcolax Tablets and Dulcolax Suppositories Bisacodyl
Consumer Medicine Information Tablets and Suppositories Bisacodyl What is in this leaflet 1. What is used for 2. Before you use a) When you must not use b) Before you start to use c) Pregnancy d) Breastfeeding
More informationDrugs Affecting the Gastrointestinal System. Antidiarrheal and Laxatives
Drugs Affecting the Gastrointestinal System Antidiarrheal and Laxatives Diarrhea Abnormal frequent passage of loose stools or Abnormal passage of stools with increased frequency, fluidity, and weight,
More informationEndoscopy Unit. Bowel Preparation Instructions for flexible sigmoidoscopy (Phosphate enema) A patient s guide
Endoscopy Unit Bowel Preparation Instructions for flexible sigmoidoscopy (Phosphate enema) A patient s guide This booklet contains the instructions you must follow to have your bowel cleaned for a flexible
More informationCT Colonography (Virtual Colonoscopy) with Gastrografin Preparation
CT Colonography (Virtual Colonoscopy) with Gastrografin Preparation Information for patients X-Ray Department Phone no: 661371 Leaflet Ref: 11257 Published: 10/16 Review:09/19 Page 1 Patient Information
More informationCONSTIPATION. Atan Baas Sinuhaji
CONSTIPATION Atan Baas Sinuhaji Sub Division of Pediatrics Gastroentero-Hepatolgy Department of ChildHealth,School of Medicine University of Sumatera Utara MEDAN DEFECATION REGULAR PATTERN CONSTIPATION
More informationConstipation. H. David Vargas, MD. Overview
Constipation H. David Vargas, MD Overview Constipation is a very common complaint affecting upwards of 15% of all Americans. Fortunately, constipation usually is simple to avoid and easy to treat when
More informationPackage Insert. Constipeg
Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF
More informationChapter 22. Bowel Needs. Copyright 2019 by Elsevier, Inc. All rights reserved.
Chapter 22 Bowel Needs Copyright 2019 by Elsevier, Inc. All rights reserved. Lesson 22.1 Define the key terms and key abbreviations in this chapter. Describe normal defecation and the observations to report.
More informationType of intervention Screening. Economic study type Cost-effectiveness analysis.
Prospective, randomized, single-blind comparison of two preparations for screening flexible sigmoidoscopy Bini E J, Unger J S, Rieber J M, Rosenberg J, Trujillo K, Weinshel E H Record Status This is a
More informationLower GI Series. National Digestive Diseases Information Clearinghouse
Lower GI Series National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is a lower gastrointestinal (GI) series? A lower GI
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationGI Physiology - Investigating and treating patients with pelvic floor dysfunction. Lynne Smith Department of GI Physiology NGH Sheffield
GI Physiology - Investigating and treating patients with pelvic floor dysfunction Lynne Smith Department of GI Physiology NGH Sheffield Aims o o o To give an overview of lower GI investigations To demonstrate
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 RELISTOR 12 mg/0.6 ml solution for injection 1 vial (CIP: 387 365-1) 2 vials + 2 sterile syringes
More informationAging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS OVERVIEW
Aging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS A major medical conditions that commonly is seen among persons with IDD and may lead to serious complications is constipation.
More informationChapter 34. Nursing Care of Patients with Lower Gastrointestinal Disorders
Chapter 34 Nursing Care of Patients with Lower Gastrointestinal Disorders Lower Gastrointestinal System Small Intestines Large Intestines Rectum Anus Constipation Fecal Mass Held In Rectum Feces Become
More informationHuman Anatomy rectum
rectum The colon is also called the large intestine. The ileum (last part of the small intestine) connects to the cecum (first part of the colon) in the lower right abdomen. The rest of the colon is divided
More informationDelorme s Operation For Rectal Prolapse
Delorme s Operation For Rectal Prolapse Patient Information Colorectal Surgery Author ID: NM Leaflet Number: Surg 045 Version: 3.1 Name of Leaflet: Delorme s Operation for Rectal Prolapse Date Produced:
More informationBiofeedback provides long term benefit for patients with intractable, slow and normal transit constipation
Gut 1998;42:517 521 517 St Mark s Hospital, London, UK E Chiotakakou-Faliakou M A Kamm AJRoy J B Storrie I C Turner Correspondence to: Dr M A Kamm, St Mark s Hospital, Northwick Park, Watford Road, Harrow,
More informationChronic constipation in the elderly
Chronic constipation in the elderly 1 Dec,2011 R 2 Natta Asanaleykha Epidemiology Definition Scope The impact of chronic constipation in the elderly Pathophysiology Evaluation the elderly patient with
More informationAngie Jefferson Registered Dietitian & Consultant Nutritionist
Angie Jefferson Registered Dietitian & Consultant Nutritionist Constipation & Haemorrhoids are two of the most common problems experienced by pregnant women Incidence increases dramatically 40% women reportedto
More informationColonoscopy. In the work-up of intestinal disorders For prevention and early recognition of colon cancer
The informed patient Colonoscopy In the work-up of intestinal disorders For prevention and early recognition of colon cancer How do I prepare for the examination? How is the examination performed? Colonoscopy
More informationEpisode 3.2 Show Notes Constipation
Episode 3.2 Show Notes Constipation Presented by: Dr Jo Preston, Dr Iain Wilkinson & Mairéad O Malley Faculty: Clare Watson, Wendy Grosvenor Guest faculty: Dr Gaggandeep Singh Alg Broadcast Date: 28th
More informationConstipation. Self-study course
Constipation Self-study course 2 Course objectives: At the end of this course you will be able to: 1. Define the term constipation 2. Explain three reasons why older adults are at greater risk for constipation
More informationPRESCRIBING INFORMATION LAX-A-DAY
PRESCRIBING INFORMATION LAX-A-DAY Polyethylene Glycol 3350 Powder for Oral Solution Laxative Pendopharm, Division of Pharmascience Inc. 6111 Royalmount Ave., Suite 100 Montreal, Quebec H4P 2T4 Date of
More informationSUPPLEMENTARY INFORMATION Associated with
Table1: Rome III and Rome IV diagnostic criteria for IBS, functional constipation and functional dyspepsia. Rome III diagnostic criteria 1,2 Rome IV diagnostic criteria 3,4 Diagnostic criteria for IBS
More informationMeasurement of colonic transit time with the Transit-Pellets TM method
Measurement of colonic transit time with the Transit-Pellets TM method Measurement of colonic transit time is an important investigation in clinical gastroenterology. The measurement is indicated particularly
More informationAre you aware there are many different reasons for having irregular bowels? This chart is to help you get back into balance during and post detox.
BRISTOL POOP CHART The Bristol Poop Chart was created in the United Kingdom by a group of gastroenterologists at the University of Bristol. This chart is designed to help you determine the health of your
More informationNeurogenic Bowel: What You Should Know. A Guide for People with Spinal Cord Injury
Neurogenic Bowel: What You Should Know A Guide for People with Spinal Cord Injury Why Is This Information Important? Before SCI, you didn t have to think about bowel movements After SCI, you may need more
More informationGas and Flatulence Prevention Diet
Gas and Flatulence Prevention Diet Purpose Intestinal gas means different things to different people. Patients may complain of excessive bloating after eating, belching, or rectal gas (flatulence), or
More informationSYMPROIC (naldemedine tosylate) oral capsule
SYMPROIC (naldemedine tosylate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationOpioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital
Opioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital 21-04-2016 MidCentral District Health Board 1 Overview Patient Experience Opioid Collaborative Constipation defined Opioid
More informationPackage leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000
Package leaflet: Information for the user Omnilax 10 g powder for oral solution, sachet Macrogol 4000 Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationComparing the efficacy of polyethylene glycol. glycol (PEG), magnesium hydroxide, lactulose. treatment of functional constipation in children
Original article Comparing the efficacy of polyethylene glycol (PEG), magnesium hydroxide and lactulosein treatment of functional constipation in children Hossein Saneian 1, Neda Mostofizadeh 2 1 Assistant
More informationForeword. Bowel Management
2 Bowel Management Foreword The section on is very similar to that of Bladder Care and Management section, as there are many issues to be addressed. You should always remember that what works for one individual
More informationGeneral Surgery. Haemorrhoids
General Surgery Haemorrhoids Hemorrhoids_PRINT.indd 1 5/9/2016 5:50:45 PM A painful problem Haemorrhoids, cushions of swollen veins in the anal canal, are often a source of embarrassment. They shouldn
More informationPatient Information Leaflet. Treating Rectal Prolapse Delormes Operation
Patient Information Leaflet Treating Rectal Prolapse Delormes Operation Treating Rectal Prolapse - Delormes operation What is a rectal prolapse? A rectal prolapse occurs when the normal supports of the
More informationA patient s guide to the. management of constipation following surgery
A patient s guide to the management of constipation following surgery This leaflet has been designed to give you more information about using laxatives after your surgery. What is constipation? After your
More informationDIETARY ADVICE FOR CONSTIPATION
Leicestershire Nutrition and Dietetic Services DIETARY ADVICE FOR CONSTIPATION What is constipation? Constipation is one of the most common digestive complaints and it can affect people of all ages. Bowel
More informationEach 5 ml contains lactulose 3.3 g, and lesser amounts of other sugars including lactose, galactose, tagatose and epilactose.
Actilax Lactulose PRODUCT INFORMATION Composition Each 5 ml contains lactulose 3.3 g, and lesser amounts of other sugars including lactose, galactose, tagatose and epilactose. Description Lactulose solution
More informationConstipation. What is constipation? What causes constipation? How common is constipation?
Constipation What is constipation? Constipation is the word we use to describe any difficulty having a bowel movement. This does not just mean infrequent bowel movements, (two or fewer bowel movements
More informationDelormes Operation for Rectal Prolapse
Delormes Operation for Rectal Prolapse Your Questions Answered What is a rectal prolapse? A rectal prolapse occurs when the normal supports of the rectum become weakened, allowing the muscle of the rectum
More informationThe Secrets of your Irritable Bowel Syndrome (IBS)
The Secrets of your Irritable Bowel Syndrome (IBS) Dr Simon Greenfield Consultant Gastroenterologist Spire Harpenden Hospital Pinehill Hospital, Hitchin QE2 Hospital, Welwyn Garden Lister Hospital, Stevenage
More informationBisacodyl Laxative (Pharmacy Health)
Bisacodyl Laxative (Pharmacy Health) Each Enteric Coated Tablet contains 5 mg Bisacodyl BP/Ph. Eur Gastro resistant Tablets What is in this leaflet This leaflet answers some common questions about Bisacodyl
More informationwho where symptoms? colon cancer facts affected? what
who Over 130,000 new cases diagnosed each year is Greater than 50,000 deaths annually attributable to colon cancer Second leading cause of cancer death in the U.S. Equal risk in men and women Women over
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationABC of palliative care: Constipation and diarrhoea
BMJ 1997;315:1293-1296 (15 November) Clinical review ABC of palliative care: Constipation and diarrhoea Marie Fallon, Bill O'Neill Prevalence of constipation Top Prevalence of constipation Assessment of
More informationBarium Enema Examination
Radiology Department Barium Enema Examination Information for patients Barium Enema examination The X-ray department has received a request for you to have a Barium Enema examination. This leaflet tells
More informationDULCOLAX Tablets and Suppositories Bisacodyl
New Zealand Consumer Medicine Information DULCOLAX Tablets and Suppositories Bisacodyl What is in this leaflet This leaflet answers some common questions about DULCOLAX. It does not contain all available
More informationEvaluation of Efficacy Variables in Clinical Study of Irritable Bowel Syndrome with Diarrhea
Evaluation of Efficacy Variables in Clinical Study of Irritable Bowel Syndrome with Diarrhea January 2018 Motoko IDA Evaluation of Efficacy Variables in Clinical Study of Irritable Bowel Syndrome with
More informationBowel Function After Spinal Cord Injury
Bowel Function After Spinal Cord Injury A resource for individuals with SCI and their supporters This presentation is based on SCI Model Systems research and was developed with support from the National
More informationMANAGING CONSTIPATION
MANAGING CONSTIPATION INFORMATION FOR OLDER ADULTS, FAMILIES, AND CAREGIVERS READ THIS PAMPHLET TO LEARN: What Constipation is. The Symptoms of Constipation. How to Help Manage Constipation. WHAT IS CONSTIPATION?
More informationMale Symptom Monitor
Male Symptom Monitor Occupation: Recreational Activities: Presenting problems: 1. 2. When did this start? Please fill out each section that is relevant to your problem Have you had any of the following
More informationPolicy #: 049 Latest Review Date: April 2009 Policy Grade: Active policy but no longer scheduled for regular literature reviews and update.
Name of Policy: Pulsed Irrigation Evacuation (PIE) Policy #: 049 Latest Review Date: April 2009 Category: DME Policy Grade: Active policy but no longer scheduled for regular literature reviews and update.
More informationA painful problem. Symptoms of haemorrhoids. Causes of haemorrhoids. Your evaluation
A painful problem Haemorrhoids, cushions of swollen veins in the anal canal, are often a source of embarrassment. They shouldn t be they re a very common problem that affects all kinds of people, including
More informationPrimary Care Constipation Guidelines. Version 1 November 2016
Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and
More informationConstipation in early childhood: patient characteristics, treatment, and longterm follow up
1400 Gut 1993; 34:1400-1404 Constipation in early childhood: patient characteristics, treatment, and longterm follow up Department of Pediatrics, University of Iowa, USA V Loening-Baucke Correspondence
More information